Profit Or Loss [Abstract]

Xbrane Biopharma - Filing #689992

Concept	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31
Profit or loss [abstract]
Profit (loss) [abstract]
Revenue	—	57 618 SEK	10 709 SEK	—
Gross profit	—	57 618 SEK	10 709 SEK	—
Other income	—	20 914 SEK	4 848 SEK	—
Administrative expenses	—	31 538 SEK	31 395 SEK	—
Other expense, by function	—	13 563 SEK	4 126 SEK	—
Profit (loss) from operating activities	—	166 217 SEK	180 583 SEK	—
Finance costs	—	2 296 SEK	2 643 SEK	—
Profit (loss) before tax	—	168 513 SEK	183 226 SEK	—
Tax expense (income)	—	– SEK	– SEK	—
Profit (loss) from continuing operations	—	168 513 SEK	183 226 SEK	—
Profit (loss) from discontinued operations	—	4 001 SEK	5 150 SEK	—
Profit (loss)	172 513 SEK	172 513 SEK	188 376 SEK	188 376 SEK
Profit (loss), attributable to [abstract]
Profit (loss), attributable to owners of parent	—	172 513 SEK	188 376 SEK	—
Profit (loss), attributable to non-controlling interests	—	– SEK	– SEK	—
Earnings per share [text block]	—	—	—	—
Earnings per share [abstract]
Earnings per share [line items]
Basic earnings per share [abstract]
Basic earnings (loss) per share from continuing operations	—	659.00	777.00	—
Basic earnings (loss) per share	—	675.00	798.00	—
Diluted earnings per share [abstract]
Diluted earnings (loss) per share from continuing operations	—	659.00	777.00	—
Diluted earnings (loss) per share	—	675.00	798.00	—